Recombinant Human Mesothelin(MSLN),partial (Active)

1. Elevated plasma MSLN level is related with epithelial ovarian cancer. PMID: 30319054
2. We have demonstrated that a rising serum mesothelin is a sensitive marker of progression in the follow up of patients with MPM. PMID: 29454314
3. we engineered variants of the fibronectin type III domain (Fn3) non-antibody protein scaffold to bind to mesothelin with high affinity, using directed evolution and yeast surface display PMID: 29738555
4. Our goal was to stimulate antitumor immunity by combining SS1P or LMB-100 with anti-CTLA-4. We constructed a BALB/c breast cancer cell line expressing human mesothelin (66C14-M), which was implanted in one or two locations. SS1P or LMB-100 was injected directly into established tumors and anti-CTLA-4 administered i.p. In mice with two tumors, one tumor was injected with immunotoxin and the other was not. PMID: 28674083
5. Mesothelin-targeted immunotoxin RG7787 increases pancreatic cancer cell sensitivity to taxane-mediated killing by increasing taxane-mediated microtubule stability and priming cells for apoptosis by decreasing levels of the pro-survival factor Mcl-1. PMID: 27999204
6. RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response. These results indicate that this combination could be useful for treating patients with mesothelioma PMID: 27635089
7. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. PMID: 28929447
8. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.( PMID: 28287406
9. MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth. PMID: 28125734
10. we report herein that high tumor mesothelin expression predicts a shorter PFS and OS in EOC patients and demonstrates that serum mesothelin predicts local tumor mesothelin expression. PMID: 28160193
11. We provide new evidence for the role of MSLN in EMT regulation, tumorigenesis and metastasis. Knockdown of MSLN led to mesenchymal to epithelial transition and less aggressive behavior of lung carcinoma and mesothelioma cells. PMID: 28288645
12. MSLN expression increases cell migration and invasion in vitro. PMID: 27422997
13. SMRP but not FBLN3 has a role in pleural effusions in in malignant pleural mesothelioma PMID: 28314308
14. High mesothelin expression is associated with malignant pleural mesothelioma. PMID: 27646775
15. Calretinin, D2-40 and mesothelin are aberrantly expressed in a proportion of CRC cases. PMID: 27062033
16. Our results showed that IMP3 immunostaining has a higher sensitivity and specificity than mesothelin for the diagnosis of pancreatic ductal adenocarcinoma. IMP3 and mesothelin may be useful markers in distinguishing neoplastic from reactive lesions of the pancreas in instances where this is impossible by morphology alone in surgical pathology practice. PMID: 26874572
17. Results indicate a specific mesothelin-driven tumor uptake of targeted 89zirconium-labeled antibody which visualizes mesothelin expressing pancreatic cancer in real time. PMID: 26536664
18. Data indicate that triple-negative breast cancer (TNBC) showed the highest amplification rate (42%) in the basal-like 1 subtype. PMID: 26172299
19. There was a trend toward elevation of SMRP values in healthy individuals exposed to asbestos compared to those without exposure. Within asbestosis cases, those with higher profusion scores had higher SMRP values than those with lower profusion scores. PMID: 26188910
20. High mesothelin expression was strongly associated with mutant KRAS/wild-type EGFR and poor prognosis in advanced lung cancer. PMID: 26028668
21. findings replicate association between rs1057147 and soluble mesothelin related peptide(SMRP)levels; SMRP performance as diagnostic biomarker for malignant pleural mesothelioma improved by considering genotype rs1057147; this polymorphism most likely affects a binding site for miR-611 PMID: 25436799
22. Expression of mesothelin was observed in 42.3% of patients with triple negative breast cancer. PMID: 25776500
23. Patients with mesothelin-positive triple negative breast carcinomas (TNBC) were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. PMID: 25506917
24. Delivery of mesothelin-targeted CAR T cells eradicates tumors in mice with pleural malignancies. PMID: 25378643
25. Pleural fluid mesothelin may serve as a marker for pleural malignant mesothelioma. PMID: 25505814
26. Patients with colon cancer had significantly higher mesothelin serum levels than the control groups. PMID: 25477701
27. Mesothelin expression is associated with poor outcomes in breast cancer.Mesothelin is a prognostic breast tumor marker whose expression is highly enriched in triple negative breast cancer tumors. PMID: 25193277
28. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. PMID: 25227779
29. Both the serum CA125(meso) level and the ratio of the serum CA125(mesothelin) to CA125 levels (CA125(mesothelin) /CA125) were significantly higher in patients with EOC. PMID: 25197000
30. Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel for pancreatic cancer. PMID: 24308545
31. MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. PMID: 24465798
32. Being negative/focally positive for mesothelin expression was associated with longer postoperative survival than positive expression in patients with cholangiocellular carcinoma. Mesothelin positivity was a predictor of short postoperative survival. PMID: 23701154
33. Our findings suggest that MLSN can be used as a marker of neoplastic transformation of epithelial cells in pancreatic mucinous cysts. PMID: 25125620
34. MSLN expression in patients with early-stage lung adenocarcinoma is associated with increased risk of recurrence and reduced overall survival. PMID: 24334761
35. These data provides evidence for the use of mesothelin as an immunogen for tumour-specific T cell response. PMID: 24520352
36. Mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. PMID: 23512344
37. In the gastric cancer tissues, C-ERC/mesothelin expression was associated with lymphatic invasion. N-ERC/mesothelin was secreted into the supernatants of gastric cancer cell lines, but does not appear to be a useful serum marker of gastric cancer. PMID: 24146039
38. Use of S100P and mesothelin in cytologically borderline cases can increase the diagnostic accuracy for pancreatic adenocarcinoma. PMID: 21538952
39. Data indicate that biochemical markers significantly associated with mesothelioma were hyaluronan, N-ERC/mesothelin and syndecan-1. PMID: 23991032
40. PE-SMRP adds some clinical information in the work-up of patients with a PE of unknown origin. PMID: 23873013
41. Mesothelin expression was identified in 34% of patients with triple receptor negative breast cancer. PMID: 23810431
42. addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with multiple myeloma PMID: 24324091
43. These data suggest that in difficult diagnostic cases both PAX2 and mesothelin immunohistochemical study may be useful in discriminating between PMRCC and primary pancreatic carcinoma. PMID: 24344503
44. SMRP could improve CYFRA 21-1 antigen and carcinoembryonic antigen (CEA) accuracy in the differential diagnosis of malignant pleural mesothelioma. PMID: 23532816
45. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. PMID: 23694968
46. Mesothelin, megakaryocyte potentiating factor and osteopontin are expressed in malignant mesothelioma [review] PMID: 22835614
47. MSLN overexpression promoted the invasive potential of MCF-7 cells through ERK1/2-dependent upregulation of MMP-9; this association may have contributed to metastasis of MCF-7 cells in vivo. PMID: 23321167
48. Data indicate that binding of mesothelin to CA125 does not alter the measurement of mesothelin for the detection of malignant mesothelioma (MM). PMID: 23357461
49. The mesothelin expression promotes resistance to certain chemotherapy drugs such as TNF-alpha, paclitaxel, and a combination of platinum and cyclophosphamide. PMID: 22721387
50. SMRP was lower in healthy subjects than in subjects with malignant tumors, asbestos-related pleural lesions, and other benign diseases PMID: 23277285
51. poor sensitivity of SMRP found in this study suggests that further work is needed to find new candidate biomarkers for diagnosing early stage malignant mesothelioma PMID: 23093275
52. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway. PMID: 23034174
53. Soluble mesothelin-related peptide detection in MPM-PE can help the diagnosis of MPM. PMID: 23249166
54. Mesothelin appears to correlate with clinical prognostic parameters and might be useful biomarkers for therapy monitoring and, thus, could serve as attractive targets for therapy of ovarian cancer PMID: 23267165
55. Most mesothelioma tumors loose mesothelin when grown in vitro and the sensitivity of these cells to SS1P is dependent on the number of mesothelin sites/cell. PMID: 23225411
56. the expression pattern level of mesothelin, i.e., in luminal membrane or cytoplasm both high and low level, evidently indicate the patient prognosis of extrahepatic bile duct cancer. PMID: 23064529
57. MUC1 and MSLN were superior to pathologic features and other putative biomarkers as predicting survival group. PMID: 22792233
58. Mesothelin levels in urine are affected by impaired glomerular and tubular function, which can influence the interpretation of mesothelin measurements and might cause false-positive resul PMID: 22386954
59. In epithelioid mesotheliomas, 13% of cells expressed nestin, 39% EMA and 7% mesothelin PMID: 22113177
60. structural and mechanistic analysis of recognition of mesothelin by the therapeutic antibody MORAb-009 PMID: 22787150
61. High SMRP is associated with mesothelioma in pleural effusions. PMID: 22729037
62. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in epithelioid pleural mesothelioma patients. PMID: 22371455
63. Serum mesothelin and MPF do not appear to be useful biomarkers for pancreatic and biliary cancers PMID: 22149739
64. High mesothelin is associated with Barrett's associated esophageal adenocarcinoma. PMID: 22237988
65. Studies indicate that the limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. PMID: 22351743
66. Review/Meta-Analysis: In patients suspected of having pleural mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. PMID: 22412141
67. Soluble mesothelin-related peptides may be a useful tumor marker for detecting the progression of malignant mesothelioma and evaluating tumor response to treatment. PMID: 22377706
68. we identified two specific genes, MUC16 and mesothelin, associated with the invasion process in patients with PDAC. PMID: 22320398
69. correlation between MSLN and MMP-7 in the progression of ovarian cancer, and the mechanism of MSLN in enhancing ovarian cancer invasion PMID: 21999204
70. Finding suggests that co-expression of mesothelin and CA125 plays a significant role in the acquisition of aggressive clinical behavior. PMID: 21775916
71. GPR30 is more sensitive, but less specific than mesothelin for pancreatic adenocarcinoma PMID: 21632639
72. The mesothelin appeared in maturing epithelial cells and characterized nests of tumor cells. PMID: 20943257
73. High mesothelin is associated with gastric cancer. PMID: 21780126
74. These results demonstrate that MSLN is normally methylated in the pleura, and that methylation is lost in most tumors. PMID: 21775819
75. High mesothelin is associated with mesothelioma. PMID: 21841505
76. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappa-B activation and IL-6/Mcl-1 overexpression PMID: 21880146
77. elevated plasma levels in malignant mesothelioma patients PMID: 21397972
78. elevated serum levels is in individuals with renal impairment PMID: 21333373
79. the aim of this study was to investigate the association between single nucleotide polymorphisms within the promoter-5'UTR regions and SMRP levels in healthy asbestos-exposed individuals and patients with malignant pleural mesothelioma. PMID: 21574151
80. using a panel of PC cells with varying MSLN/IL-6 expressions, we showed that MSLN/IL-6 axis is a major survival axis in PC supporting tumor cell growth under anchorage-dependent and independent conditions PMID: 21515913
81. High mesothelin is associated with renal failure in mesothelioma. PMID: 21508397
82. Data suggested that the cause of MSLN cancer-specific overexpression might also contribute mechanistically to the overexpression of other tumor markers. PMID: 21288909
83. miR-126, in association with soluble mesothelin-related peptides, as a marker for early detection of malignant pleural mesothelioma PMID: 21483773
84. Elevated levels of mesothelin is associated with ovarian carcinoma in patients with pelvic masses. PMID: 20593939
85. Investigated whether N-ERC (the 30 kDa N-terminal secretory form of ERC/mesothelin) could function as a secretory factor to stimulate tumor progression. PMID: 20596597
86. Hypomethylation of the MSLN promoter may be specifically associated with the formation of malignant mesothelioma. PMID: 20573372
87. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein PMID: 19858537
88. A correlation was found between mesothelin expression and the average methylation/hypomethylation status as well as methylation/hypomethylation status at four of 20 CpG sites in ovarian samples. No correlation was found in endometrial samples PMID: 20349783
89. SMRP is characterterized as a biomarker for malignant mesothelioma in human PMID: 20131968
90. Expression of MESO mRNA and protein is increased in ovarian carcinomas and borderline ovarian tumors. PMID: 18788634
91. Data show that mesothelin is a potential target in reducing resistance to cytotoxic drugs, and mesothelin-treated cells revealed rapid tyrosine phosphorylation of the p85 subunit of PI3K. PMID: 19747165
92. binding of membrane-bound mesothelin to ovarian cancer antigen CA125 mediates heterotypic cell adhesion PMID: 14676194
93. mesothelin is highly expressed in several human cancers [review] PMID: 15217923
94. Elevated serum mesothelin is associated with mesothelioma and ovarian cancer PMID: 16428485
95. The mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma. PMID: 16467095
96. MSLN, a tumor marker, is also used as a target for immunotherapy. PMID: 16638849
97. MPF is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma PMID: 16857795
98. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. PMID: 17067392
99. Mesothelin was expressed in 5 (50%) of 10 adenocarcinomas, 1 (17%) of 6 high-grade dysphasia/adenocarcinoma in situ cases, and 0 low-grade dysplasia. PMID: 17276942
100. We present evidence that during cell division the decreasing activity of MPF acts as a master signal, which utilizes different thresholds to control initiation of different mitotic events. The key temporal control here is the degradation of cyclin B1. PMID: 17598982

Show More

Hide All

HGNC: 7371

OMIM: 601051

KEGG: hsa:10232

STRING: 9606.ENSP00000372313

UniGene: Hs.408488